Microbot Medical financials
$1.25−0.40%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | — | — | — | — | — | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | — | — | — | — | — | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$14.7M | -$11.6M | -$9.9M | -$13.3M | -$11.4M | -$9.1M | -$7.2M | -$7.2M | -$3.1M | -$32.6K |
| Net income | -$13.1M | -$11.4M | -$10.7M | -$13.2M | -$11.3M | -$9.2M | -$7.2M | -$7.0M | -$5.1M | -$47.8K |
| Net margin | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-0.29 | $-0.73 | $-1.05 | $-1.81 | $-1.59 | $-1.29 | $-1.70 | $-2.41 | $-27.72 | $-0.36 |
| EBITDA | -$14.7M | -$11.5M | -$9.7M | -$13.2M | -$11.3M | -$9.0M | -$7.2M | -$7.2M | -$3.1M | -$32.6K |
| Operating cash flow | -$13.0M | -$8.8M | -$8.5M | -$11.5M | -$9.4M | -$7.3M | -$6.5M | -$5.3M | -$2.1M | -$21.1K |
| Free cash flow | -$13.1M | -$8.9M | -$8.6M | -$11.6M | -$9.4M | -$7.3M | -$6.7M | -$5.5M | — | — |
| Diluted shares | 45.8M | 15.6M | 10.2M | 7.3M | 7.1M | 7.1M | 4.3M | 2.9M | 0.2M | 0.1M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $3.9M | $3.1M | $2.5M | $2.4M | $13.5M | $19.6M |
| Short-term investments | $74.7M | $2.4M | $3.9M | $5.8M | $2.0M | $5.0M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $81.5M | $6.0M | $8.3M | $9.5M | $16.8M | $26.3M |
| Total liabilities | $4.0M | $2.5M | $3.8M | $2.2M | $2.4M | $2.0M |
| Shareholders' equity | $77.6M | $3.5M | $4.5M | $7.3M | $14.4M | $24.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology